Estradiol levels increased continuously only in the treatment group ( P < 0.005), indicating an improvement of ovulatory function. four of six) had no significant amelioration of their menstrual irregularities ( P < 0.05). three of 17), whereas women without IR (four of seven vs. Results: The main outcome criterion menstrual disturbance was successfully improved in the metformin-treated group, depending on IR (12 of 15 vs. Main Outcome Measures: Menstrual disturbance and markers of insulin metabolism were measured. Interventions: Women were stratified for IR (32 of 13) and then randomly allocated to receive either metformin (n = 22) or placebo (n = 23) and were assessed before and every 4 wk within a treatment period of 12 wk. Patients: The patient population was 45 oligo-/anovulatory PCOS women with typical ovaries. Setting: The study was conducted at the University of Heidelberg, Heidelberg, Germany. Objective: The objective of the study was to evaluate the early potential effects of metformin treatment, their time of onset, and the role of IR on metformin’s efficacy.ĭesign: This was a prospective randomized, double-blind, placebo-controlled trial. No data of the exact point and the impact of insulin resistance (IR) on metformin’s efficacy exist. Context: Metformin is successfully used in the treatment of cycle disorders and anovulation in women with polycystic ovary syndrome (PCOS).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |